Home
|
Help
|
Contact
Sign in
WPRIM Management System>
DCMS
>
Journal of Gynecologic Oncology
>
>
22
Volume:
22
1. Chylous ascites following robotic lymph node dissection on a patient with metastatic cervical carcinoma.
Page:61—63
2. Early port-site metastasis during neoadjuvant chemotherapy in advanced stage ovarian cancer: report of two cases.
Page:57—60
3. A case of minimal uterine serous carcinoma with distant lymph node metastasis without peritoneal dissemination.
Page:53—56
4. Guideline adherence to chemotherapy administration safety standards: a survey on nurses in a single institute.
Page:49—52
5. Clinical significance of HIF-2alpha immunostaining area in radioresistant cervical cancer.
Page:44—48
6. Pap smear screening for small cell carcinoma of the uterine cervix: a case series and review of the literature.
Page:39—43
7. Is human papillomavirus genotype an influencing factor on radiotherapy outcome? Ambiguity caused by an association of HPV 18 genotype and adenocarcinoma histology.
Page:32—38
8. The safety of conization in the management of adenocarcinoma in situ of the uterine cervix.
Page:25—31
9. Differences in perioperative outcomes after laparoscopic management of benign and malignant adnexal masses.
Page:18—24
10. Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.
Page:9—17
11. Multivariate survival analysis of the patients with recurrent endometrial cancer.
Page:3—8
12. Cervical adenocarcinoma in situ with negative conization margin: negligible or not?.
Page:1—2
13. The role of neoadjuvant chemotherapy in ovarian cancer patients with extensive tumor burden.
Page:299—300
14. Paratubal serous borderline tumor.
Page:295—298
15. Long-term recurrence-free survival in a patient with stage IVB uterine carcinosarcoma.
Page:292—294
16. A mediastinal germ cell tumor mimicking an ectopic pregnancy.
Page:288—291
17. Diffusion-weighted MR imaging in gynecologic cancers.
Page:275—287
18. Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer.
Page:269—274
19. Thoracic metastasis in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery.
Page:260—268
20. Total laparoscopic hysterectomy versus da Vinci robotic hysterectomy: is using the robot beneficial?.
Page:253—259
21. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass.
Page:244—252
22. Survival outcome of women with synchronous cancers of endometrium and ovary: a 10 year retrospective cohort study.
Page:239—243
23. Synchronous gynecologic malignancy and preliminary results of Lynch syndrome.
Page:233—238
24. Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro.
Page:225—232
25. ASGO's Second Biennial Meeting, November 3-5 2011.
Page:222—224
26. Recent advances in the biomarkers for epithelial ovarian cancer.
Page:219—221
27. Prolonged survival following maximal cytoreductive effort for peritoneal metastases from recurrent granulosa cell tumor of the ovary.
Page:214—217
28. Squamous cell carcinoma of the vulva in a virgin patient with Turner syndrome.
Page:211—213
29. Pediatric vulvar squamous cell carcinoma in a liver transplantation recipient: a case report.
Page:207—210
30. Chemo-resistant choriocarcinoma metastatic to colon cured by low-anterior resection.
Page:203—206
31. The impact of robotic surgery on gynecologic oncology.
Page:196—202
32. Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study.
Page:188—195
33. Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?.
Page:183—187
34. Comparison of four malignancy risk indices in the detection of malignant ovarian masses.
Page:177—182
35. Laparoscopic surgery for endometrial cancer: increasing body mass index does not impact postoperative complications.
Page:168—176
36. Prognostic significance of syndecan-1 expression in cervical cancers.
Page:161—167
37. Health-related quality of life and late morbidity in concurrent chemoradiation and radiotherapy alone in patients with locally advanced cervical carcinoma.
Page:152—160
38. Visual inspection with acetic acid for detection of high grade lesion in atypical squamous cells and low grade squamous intraepithelial lesions from cervical Pap smear.
Page:145—151
39. Granulosa cell tumor of the ovary: time to launch a new prospective trial.
Page:143—144
40. Quality of life in gynecologic cancer survivors compared to healthy check-up women.
Page:103—109
41. Major surgeries performed for gestational trophoblastic neoplasms in a teaching hospital in Tehran, Iran.
Page:97—102
42. Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid endometrial cancers and clinicopathologic significance.
Page:89—96
43. Which is worse: uterine papillary serous carcinomas or carcinosarcomas?.
Page:83—88
44. Cervical cancer in the screening era: who fell victim in spite of successful screening programs?.
Page:76—82
45. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women.
Page:67—75
46. Robotic single-site surgery: from research to clinical practice?.
Page:65—66
47. Discharge criteria should be validated in patients who undergo ambulatory gynecologic surgery.
Page:140—141
48. Pure choriocarcinoma of the ovary: a case report.
Page:135—139
49. Sonographic diagnosis and Endo-SPONGE assisted vacuum therapy of anastomotic leakage following posterior pelvic exenteration for ovarian cancer without using a protective stoma.
Page:131—134
50. Single-port access laparoscopic staging operation for a borderline ovarian tumor.
Page:127—130
51. Robotic single-port transumbilical total hysterectomy: a pilot study.
Page:120—126
52. Combined effect of CYP1B1, COMT, GSTP1, and MnSOD genotypes and risk of postmenopausal breast cancer.
Page:110—119